The Majority of Infiltrating CD8 T Lymphocytes in Multiple Sclerosis Lesions is Insensitive to Enhanced PD-L1 Levels on CNS Cells
Affiliations
Central nervous system (CNS) cells locally modulate immune responses using numerous molecules that are not fully elucidated. Engagement of programmed death-1 (PD-1), expressed on activated T cells, by its ligands (PD-L1 or PD-L2) suppresses T-cell responses. Enhanced CNS PD-1 and PD-L1 expression has been documented in inflammatory murine models; however, human CNS data are still incomplete. We determined that human primary cultures of astrocytes, microglia, oligodendrocytes, or neurons expressed low or undetectable PD-L1 under basal conditions, but inflammatory cytokines significantly induced such expression, especially on astrocytes and microglia. Blocking PD-L1 expression in astrocytes using specific siRNA led to significantly increased CD8 T-cell responses (proliferation, cytokines, lytic enzyme). Thus, our results establish that inflamed human glial cells can express sufficient and functional PD-L1 to inhibit CD8 T cell responses. Extensive immunohistochemical analysis of postmortem brain tissues demonstrated a significantly greater PD-L1 expression in multiple sclerosis (MS) lesions compared with control tissues, which colocalized with astrocyte or microglia/macrophage cell markers. However, more than half of infiltrating CD8 T lymphocytes in MS lesions did not express PD-1, the cognate receptor. Thus, our results demonstrate that inflamed human CNS cells such as in MS lesions express significantly elevated PD-L1, providing a means to reduce CD8 T cell responses, but most of these infiltrating immune cells are devoid of PD-1 and thus insensitive to PD-L1/L2. Strategies aimed at inducing PD-1 on deleterious activated human CD8 T cells that are devoid of this receptor could provide therapeutic benefits since PD-L1 is already increased in the target organ.
Therapeutic Targeting of Glioblastoma and the Interactions with Its Microenvironment.
Genoud V, Kinnersley B, Brown N, Ottaviani D, Mulholland P Cancers (Basel). 2023; 15(24).
PMID: 38136335 PMC: 10741850. DOI: 10.3390/cancers15245790.
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.
Daei Sorkhabi A, Komijani E, Sarkesh A, Shadbad P, Aghebati-Maleki A, Aghebati-Maleki L Cell Commun Signal. 2023; 21(1):321.
PMID: 37946301 PMC: 10634124. DOI: 10.1186/s12964-023-01289-9.
Smith B, Tinkey R, Brock O, Mariam A, Habean M, Dutta R J Neuroinflammation. 2023; 20(1):234.
PMID: 37828609 PMC: 10568873. DOI: 10.1186/s12974-023-02917-4.
Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, Losslein L, Vandrey O Nat Commun. 2023; 14(1):5555.
PMID: 37689786 PMC: 10492803. DOI: 10.1038/s41467-023-40982-8.
Women in the field of multiple sclerosis: How they contributed to paradigm shifts.
Barateiro A, Barros C, Pinto M, Ribeiro A, Alberro A, Fernandes A Front Mol Neurosci. 2023; 16:1087745.
PMID: 36818652 PMC: 9937661. DOI: 10.3389/fnmol.2023.1087745.